- Medical news & Guidelines
- Cardiology and CTVS
- Critical Care
- Diabetes and Endocrinology
- Laboratory Medicine
- Health news
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Dadra and Nagar Haveli
- Daman and Diu
- Himachal Pradesh
- Jammu & Kashmir
- Madhya Pradesh
- Tamil Nadu
- Uttar Pradesh
- West Bengal
- Medical Education
Karkinos Healthcare launches HPV test CerviRaksha priced at Rs 2499
CerviRaksha HPV test identifies the high-risk HPV-16 and HPV-18 genotypes individually.
Mumbai: Karkinos Healthcare - a technology driven oncology-focused managed health care platform, has introduced CerviRaksha, a first-of-its-kind clinically validated HPV test, in partnership with Karkinos' network hospitals, doctors, and corporates. The test is pre-qualified by the World Health Organisation (WHO) and approved by the Food and Drug Administration, USA (FDA) and was...
Mumbai: Karkinos Healthcare - a technology driven oncology-focused managed health care platform, has introduced CerviRaksha, a first-of-its-kind clinically validated HPV test, in partnership with Karkinos' network hospitals, doctors, and corporates.
The test is pre-qualified by the World Health Organisation (WHO) and approved by the Food and Drug Administration, USA (FDA) and was also granted the CE mark meeting European Health Standards.
"And for the first time in HPV testing, sample collection at home is made possible to encourage more women to participate in this screening," the company said in its recent release.
A medically trained "CerviRakshak" will perform the sample collection from the comfort of the applicant's home and the applicant will receive test results via email in 7 days from the date of shipping the collected sample.
According to the company, CerviRaksha HPV test also identifies the high-risk HPV-16 and HPV-18 genotypes individually. This enables the gynecologists to plan the treatment protocols accordingly. There is an inbuilt filtering of false positives and false negatives for additional accuracy.
Priced at ₹2499, CerviRaksha ensures early detection of lesions in the cervix caused by HPV.
Commenting about the need for gold standard HPV testing methods to eliminate cervical cancer, Dr. R Sankaranarayanan, Director, Preventive Oncology at Karkinos Healthcare, said, "Among all the cancers, Cervical Cancer is completely curable, only if detected early. However, in India, the yearly incidence rate of cervical cancer is 18% and the yearly mortality rate is 11.4%, which could be unquestionably brought down to a great extent in the next five years, if only we generate enough awareness about the efficacy rate of HPV Test. Because of its high negative predictive value, once tested, the chances of developing cervical precancerous lesions or cervical cancer in the next five to ten years becomes extremely low."
"The awareness of the HPV Test in India is pretty low, as it is mainly limited to higher-income groups. Karkinos Healthcare, therefore, is on a mission to democratize cancer care in India and in-sync with this mission, the company has introduced CerviRaksha HPV Test, targeted at all Indian women," says Sripriya Rao, Co-Founder and Chief Growth Officer (Women Wellness) at Karkinos Healthcare.
India accounts for nearly one-third of the global cervical cancer deaths, with women facing a 1.6% cumulative risk of developing cervical cancer and 1% cumulative death risk from cervical cancer. Studies show that 99% of cervical cancers are caused by the Human Papilloma Virus (HPV). Of the 100 known types of HPV, HPV-16 and HPV-18 account for 70% of cervical cancers globally.
Persistent HPV infection can develop into cervical precancerous lesions and cervical cancer. Of the three types of cervical cancer test methods, HPV testing is the gold-standard. It is the most preferred test by gynecologists, worldwide, owing to its clinically proven data. HPV test offers several advantages including high accuracy, early detection, and its high negative predictive value. The test paves way to better treatment protocols and boosts survival rates.
Read also: SII to seek DCGI market nod for qHPV vaccine against cervical cancer
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751